Wockhardt Ltd — Investor Presentation 2026

Jun 4, 2026

WOCKHARDT LIFE WINS

Ref. No.: WOCK/SEC/SE/2026-27/016

4th June, 2026

BSE Limited Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001 Scrip Code: 532300	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051 NSE Symbol: WOCKPHARMA

Dear Sir/ Madam,

Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended – Investor Presentation

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and in continuation to our letter bearing reference no. Ref. No.: WOCK/SEC/SE/2026-27/015 dated 1st June, 2026, please find enclosed herewith a copy of the Investor Presentation to be made at the Investor Meeting scheduled to be held on 4th June, 2026.

The said Investor Presentation will also be uploaded on the Company's website and can be accessed through the following link:

https://www.wockhardt.com/investors/analyst-investors/presentation/

Kindly take the same on record please.

Thanking you,

For Wockhardt Limited

Rashmi Digitally signed by
Rashmi Dinesh
Mamtura
Date: 2026.06.04
16:01:52 +05'30'

Rashmi Mamtura
Company Secretary

Encls: A/a

WOCKHARDT LIMITED • Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Mumbai-400051, India • T: 91-22-26534444

Regd. Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhajinagar-431006, India • T: 91-240-6694444 • F: 91-240-2489219

www.wockhardt.com • CIN: L24230MH1999PLC120720

---

WOCKHARDT | LIFE WINS

Innovation. Performance. Growth.

A Global Innovation-Led Healthcare Company

Novel Antibiotics

Pharmaceuticals

Biotechnology

Investor Conference | 04 June 2026

---

Investor Conference | 04 June 2026

WOCKHARDT LIFE WiNS

Disclaimer

This presentation contains "forward-looking statements" – that is, statements that relate to future, not past events or historical facts. All forward-looking statements are based on judgments derived from the information available to the company at this time. Forward-looking statements can be identified by terminology such as such as "potential," "expected," "will," "planned," or similar terms. Forward looking statements are based on the current beliefs and expectations of Wockhardt regarding future events, and are subject to various risks and uncertainties, many of which are difficult to predict. Actual results may differ materially from anticipated results. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. We do not undertake any obligation to update any forward-looking statement in this presentation, whether as a result of changes in underlying factors, new information, future events or otherwise. The information in this document have been collected with the purpose to provide interested parties with information about Wockhardt. The information is not comprehensive or complete and thus does not represent an adequate basis for a final decision about an investment. The presentation may not be copied, duplicated or transferred to third parties without the prior written approval of Wockhardt.

---

Investor Conference | 04 June 2026

WOCKHARDT LIFE WiNS

Agenda

• Wockhardt's Strategic Overview and Growth drivers - Dr. Murtaza Khorakiwala (Managing Director)
• Foray of Zaynich in US - Zahabiya Khorakiwala (Director)
• Zaynich Strategy in India - Annapurna Das (President- India Business & NCE Emerging Markets)
• Q&A

---

Investor Conference | 04 June 2026

WOCKHARDT | LiFE WiNS

Agenda

• Wockhardt's Strategic Overview and Growth drivers - Dr. Murtaza Khorakiwala (Managing Director)
• Foray of Zaynich in US - Zahabiya Khorakiwala (Director)
• Zaynich Strategy in India - Annapurna Das (President- India Business & NCE Emerging Markets)
• Q&A

---

Investor Conference | 04 June 2026

TWOCKHARDT LIFE WINS

Overview & Business Performance

---

Investor Conference | 04 June 2026

WOCKHARDT LIFE WINS

Global Research - driven multinational

Novel Antibiotics

World-leading discovery engine for first-in-class new chemical entities targeting antimicrobial resistance.

Biotechnology

Integrated diabetes-biosimilars franchise spanning human insulin and insulin analogues.

Pharmaceuticals

Branded and specialty pharmaceutical presence across India and global markets.

11 manufacturing facilities across globe

2 R&D centers one each in India, UK

---

Investor Conference | 04 June 2026

WOCKHARDT LIFE WINS

Key Financials

INR 3,373 Cr.

FY26 Income

51%

Y-o-Y EBITDA growth¹

INR 630 Cr.

FY26 EBITDA

0.10

Net Debt : Equity ratio²

INR 238 Cr.

FY26 PBT

INR 662 Cr.

Cash & Cash Equivalents³

1. FY26 vs FY25
2. As on 31st March 2026, excluding promoter debt
3. As at 31st March 2026

---

Investor Conference | 04 June 2026

WOCKHARDT | LiFE WiNS

Performance 01

Specialty Business growth

23%

Contribution to revenues of novel antibiotics & biosimilars

Emrok delivered strong growth of ~50%; Market leading anti-MRSA brand

27%

Biotech business growth

Production scale-up: 2x for Human Insulin & 1.5x for Glargine

---

Investor Conference | 04 June 2026

WORKHARDT LIFE WINS

Performance 02

Regional Business contribution

Regional contribution not to scale

---

Investor Conference | 04 June 2026

WOCKHARDT LIFE WINS

Performance 03

Improved Profitability

Profitability Focus

• Margin Maximization
  Focused on high-margin core products to maximise returns

• Supply Chain Optimization
  Streamlined sourcing to build cost resilience

• Exit of US Generic Business
  Divested underperforming US pharmagenerics business to sharpen portfolio focus

---

Investor Conference | 04 June 2026

WORKHARDT LIFE WINS

Performance 04

Operational Excellence

Manufacturing Re-structuring

Optimized plant capacity and footprint for efficiency gains

Cost Management

Drove systemic cost reduction through disciplined controls
- 50+ projects implemented
- AVD

Corporate-wide Improvements

Accelerated enterprise-wide transformation initiatives
- AI-led
- S4 HANA

---

Investor Conference | 04 June 2026

WOCKHARDT | LIFE WINS

Key Growth Drivers

---

Investor Conference | 04 June 2026

WOCKHARDT LIFE WINS

Looking Ahead

Objectives for the next two years — growth acceleration, sustainable operational excellence enabled by AI

Novel Antibiotics

• Launch Zaynich in the US, India, Europe and EM
• Miqnaf: Extending reach & additional indications
• Emrok & Emrok O: strengthening franchise

Pharma Business

• EU growth
• Accelerating India business

Biotech Business Accelerator

• Enhanced biotech capacity to address surge in insulin demand
• Deeper diabetes biosimilars pipeline

Operational Excellence 2.0

• People: New capabilities & talent
• AI-enabled operational excellence initiatives
• Sustainability and scalability

---

Investor Conference | 04 June 2026

WOCKHARDT | LiFE WINS

Growth 02/04

Biosimilar Diabetes Franchise

14

---

Investor Conference | 04 June 2026

WOCKHARDT | LiFE WiNS

Growth 02/04

Biosimilars portfolio and end-to-end platform

Integrated capabilities from lab to patient — a comprehensive pipeline across Human Insulin and insulin analogs

2 Commercialized products

Recombinant Insulin & Glargine

5 Pipeline assets

R&D through Phase III

30+ Emerging markets

Registered & actively supplied

Patented delivery devices (pen)

Vials

Cartridges

Pipeline Across Human Insulin & Insulin Analogs

Recombinant Human Insulin	Commercialized
Glargine	Commercialized
Aspart R	Phase III
Aspart 30/70	PK/PD study
Degludec	R&D
Degludec + Aspart	R&D
Semaglutide	R&D

---

Investor Conference | 04 June 2026

WOCKHARDT | LiFE Wins

Growth 03/04

Pharma Portfolio

---

Investor Conference | 04 June 2026

WOCKHARDT LIFE WINS

The Wockhardt Journey

2018 – 2023	2023 – 2026	2026 – Future
Liquidity Management

• Debt restructuring & deleveraging
• Asset monetization strategy
• Working capital optimization
• Cash flow stabilization | Profitability Management

• Exit US Generic Business
• Margin expansion initiatives
• Operational excellence gains
• Revenue mix improvement | Scaling Growth

• Zaynich Global Business
• Biotech Acceleration
• Pharma R&D
Differentiated pipeline
• Operational and Commercial Excellence 2.0 |

---

Investor Conference | 04 June 2026

WOCKHARDT | LiFE WiNS

Agenda

• Wockhardt's Strategic Overview and Growth drivers - Dr. Murtaza Khorakiwala (Managing Director)
• Foray of Zaynich in US - Zahabiya Khorakiwala (Director)
• Zaynich Strategy in India - Annapurna Das (President- India Business & NCE Emerging Markets)
• Q&A

---

Investor Conference | 04 June 2026

WOCKHARDT | LIFE WINS

Zaynich™ Approved by US FDA

First Indian discovered drug from lab bench to approval that catapults India in the Global spotlight

Indian Origin discovery

Best in Class

Global Impact

---

Investor Conference | 04 June 2026

WOCKHARDT LIFE WINS

USA: Commercial opportunity

~1.2 Million Gram-negative Hospital Infections in USA

Sources: Evaluation by Independent agency

---

Investor Conference | 04 June 2026

WOCKHARDT | LiFE WiNS

Clinical Development

Treatment failures combined with limited alternatives create a meaningful opportunity for Zaynich™

~40%

Treatment failure rates for empiric therapy due to carbapenem resistance in high burden settings for cUTI patients

15-25%

Polymicrobial infection complicates therapy selection

3-5x

Higher hospitalization risk in elderly, thereby bearing disproportionate morbidity

20-25%

High infection recurrence increases hospitalizations and re-admissions

Limited coverage options for all pathogens & resistance mechanisms

Sources: 1. CDC Antibiotic Resistance Threats Report 2023 2. Infectious Diseases Society of America (IDSA) Clinical Guidelines 2024 3. WHO Priority Pathogen List 4. ClinicalTrials.gov 5. ECDC Surveillance Data

---

Investor Conference | 04 June 2026

WOCKHARDT LIFE WINS

Zaynich™ tackles pan drug-resistant infections riding on its unique mechanism of action

Kills major Carbapenem resistant bacteria that other drug fails to treat

Broader coverage compared with other treatment options

Targeting multiple penicillin binding protein mechanism of action

Unlike classical BLI, Zidebactam binds to PBP2 causing bacterial cell death

Established Safety Profile

Safe for patients with multiple co-morbidities with minimal drug interactions

---

Investor Conference | 04 June 2026

WOCKHARDT LIFE WINS

Clinical Development

Zaynich™ is a novel antibiotic for Gram-negative infections coupled with a strong safety profile

Clinical Cure Rate in Global Phase III

Clinical + Microbiological Cure Rate in Phase III

Clinical Efficacy in Phase II CRO Study

Compassionate use patients cured from highly resistant infections

20% higher composite cure vs standard of the care, Meropenem

---

Investor Conference | 04 June 2026

WOCKHARDT LIFE WINS

Capabilities Development

Leadership on boarded for commercialization of Zaynich

William McNey
Chief Commercial Officer

Experience: 25+ years
Previous Organizations: IQVIA, Invivyd, Shionogi, PwC, Novartis, GSK, and Dey Pharma

Dr. Dennis Deruelle
Chief Medical Officer

Experience: 19+ years
Previous Organizations: Vitasora Health, NeuroSensa, Mendota Health, TeamHealth, American Physician Partners, and IPC

Leo Yasinski
Vice President – Market Access

Experience: 20+ years
Previous Organizations: Innoviva, La Jolla, Tetraphase Pharmaceuticals, Merck & Co., Cubist Pharmaceuticals, and Wyeth Pharmaceuticals

Sandy Estrada
Field Medical Affairs

Experience: 20+ years
Previous Organizations: CorMedix Therapeutics, Melinta Therapeutics, Heron Therapeutics, T2Biosystems, Lee Memorial Health System

---

Investor Conference | 04 June 2026

WOCKHARDT LIFE WINS

Launch excellence

Strategy to established a “competency & capability heavy, but operationally light” integrated launch architecture

Wockhardt USA Leadership team to drive strategy & execution

• Strong market access for wide penetration
• Clinical advocacy building on the strong relationship with KOLs through ad-boards

• Logistics: trade & distribution partnership (3PL) secured

• HEOR: showcasing economic benefit of Zaynich to hospital system to lower re-admission rates & average length of stay

• Deployment: Medical Science Liaison, Market Access, Sales & Marketing
• Secured Global Supply Chain: Manufacturing from US FDA approved European site

Overarching strategy to maximize hospital penetration & clinician adoption

---

Investor Conference | 04 June 2026

WOCKHARDT | LiFE WiNS

Agenda

• Wockhardt's Strategic Overview and Growth drivers - Dr. Murtaza Khorakiwala (Managing Director)
• Foray of Zaynich in US - Zahabiya Khorakiwala (Director)
• Zaynich Strategy in India - Annapurna Das (President- India Business & NCE Emerging Markets)
• Q&A

---

Investor Conference | 04 June 2026

WOCKHARDT | LIFE WINS

Zaynich® Approved by CDSCO, India

---

Investor Conference | 04 June 2026

WOCKHARDT LIFE WINS

India: Burden

India’s Carbapenem Resistance Burden : Rising CR cases and resistance trends is a reality with improving healthcare access

$\sim 1 \mathrm{Mn} +$

Total Hospitalized Infections

600K - 700K +

Gram negative infections (68% of all hospitalized patients)

$\sim 35\% - 45\%$

Carbapenem resistant infections

Organism	CR Rate (India)	Trend
Klebsiella pneumoniae	~52-70%	↑ Rising
Acinetobacter baumannii	~60-80%	Stable High
Pseudomonas aeruginosa	~25-40%	↑ Rising
Escherichia coli	~8-15%	↑ Rising

Sources: ICMR-AMR Annual Report 2022, WHO GLASS India Data 2021-23

---

Investor Conference | 04 June 2026

WOCKHARDT | LIFE WINS

It takes 2–10 years for innovation to reach Emerging Markets. We want to break the cycle.

Challenge the conventional Launch Playbook

---

Investor Conference | 04 June 2026

WORKHARDT LIFE WINS

India: Launch Plan 1/2

Zaynich Launch Priorities

Building Real world evidence (RWE) and driving right usage in right patients is not an option - it is the strategy

• Drive Accelerated Market Penetration
  Build Go-To-Market (Share of Voice & Reach) for ≥ 80% patient pool coverage

• Physician Experience Building | RWE & Hospitals / Physicians engagement

• Maximize Patient Impact : Alleviate Price as Access Barrier and drive Right Usage
  Tiered access centric pricing across public ↔ private delivery chains to drive stewardship

• PRECISION ANTIBIOTIC STEWARDSHIP | Standard of Care (SoC) • Mitigate Over & Under-usage

• Shape AMR Management Ecosystem
  Patient-centric standards across HCPs, Regulators & Policy Makers

• MULTI-STAKEHOLDER PARTNERSHIPS | AMR Management Excellence

---

Investor Conference | 04 June 2026

WOCKHARDT | LiFE WiNS

India: Launch Plan 2/2

India Patient Access Approach

CR Burden Led Access for Patient Pool in Private and Public

PUBLIC · Access for Public Payors including States

SPECIALIZED 360° R&D enabled Scientific Knowledge Roll out

RWE at Launch and LCM

Patient Access Program

Sources: Wockhardt India commercial assessment; ICMR AMR data 2024; NPPA formulary guidelines; Ayushman Bharat PMJAY inclusion criteria

---

Investor Conference | 04 June 2026

WOCKHARDT | LiFE WiNS

EM Disease Landscape

Carbapenem Resistance Burden in Emerging Markets

~1.5 Mn+ CR cases in EM markets · High unmet need for managing CR organism infections

~1.5Mn+	Estimated CR cases per year across EM’s
~10% to 40%	Resistance rates across key EM’s
$3-4 Bn	Addressable market size

• Resistance is rising rapidly across EM markets — outpacing treatment options
• Multiple resistance mechanisms make infections Hard-to-Treat or Difficult-to-Treat
• Standard antibiotics increasingly fail; creating urgent unmet clinical need

Enter 7-8 Key Markets with high CR burden in next 18-24 months

Aim for Registration & Launch:
Latin America, Eurasia, GCC and South / South East Asia markets

Sources: Lancet 2022 · O'Neill Commission 2015 · ICMR AMR 2022/2024 · WHO GLASS

---

Investor Conference | 04 June 2026

WOCKHARDT LIFE WINS

INDIA & EM a Multiplier, Not Additive

Market potential : Patient Pool

Industry-leading Launch : Patient Access

Building patient centric business and operating model delivering sizeable, sustainable and profitable revenue

Millions of patients in Emerging Markets are waiting for the right antibiotic.

Every day without access is a life at risk from carbapenem-resistant infections.

---

Investor Conference | 04 June 2026

WOCKHARDT | LiFE WiNS

---

Investor Conference | 04 June 2026

WOCKHARDT LIFE WINS

Abbreviations

®: Registered

~: Approximate

AMR: Anti Microbial Resistance

Bn: Billion

BLI: Beta Lactamase Inhibitor

CDSCO: Central Drugs Standard Control Organization

CRO: Carbapenem Resistant Organism

cUTI : Complicated urinary tract Infections

Cr.: Crore

EBITDA : Earnings before interest, taxes, depreciation, and amortization

HABP: Hospital Acquired Bacterial Pneumonia

ICMR: Indian Council of Medical Research

INR: Indian rupee

KOL: Key opinion leader

LCM: Life cycle management

MRSA: Methicillin-resistant Staphylococcus aureus

Mn – Million

NCE: New chemical entity

PBP: Penicillin-binding proteins

R&D: Research and Development

RWE: Real world evidence

TM: Trademark

UK: United Kingdom

US: United States

US-FDA: United States Food and Drug Administration

VABP: Ventilator Acquired Bacterial Pneumonia

Y-o-Y: Year-over-year